Berit Lindholm will take over as CEO of SIQ on May 23. Berit comes from Bluefish Pharmaceuticals where she has been CEO for the past five years.

Berit Lindholm is a pharmacist and has been active in the pharmaceutical industry for a long time with positions at both Astra Zeneca and Pfizer before she started as Operations Manager at Bluefish Pharmaceuticals in 2014 and took over as CEO in 2016.

During her time in the pharmaceutical industry, she and her family have lived in both the UK and India.

"During my and Bluefish Pharmaceuticals' growth journey, I have worked a lot with building processes around how to manage and develop a company with a view to sustainability and created a foundation for quality work.
To take these experiences further and work to ensure that more companies, authorities and organizations discover, and gain access to, the tools and services that SIQ offers to ensure their quality development and sustainable success was what made me choose to apply, and accept, the position as CEO of SIQ" says Berit Lindholm.

"With her genuine understanding of the basis of sustainable success through systematic quality work and with her broad experience from research to production, market and sales - both nationally and internationally - Berit is the right person to lead SIQ in the continued focus on quality development in business and the public sector," says SIQ's Chairman of the Board Anna Nilsson-Ehle.

Berit Lindholm will take office on May 23, 2022. Göran Lundwall, who has acted as interim CEO during the recruitment and accession period, will resume his place on the SIQ board in connection with this.

For questions contact; Anna Nilsson-Ehle, Chairman of the Board SIQ, anna@nilsson-ehle.se, 0709 96 76 00.